BP Med for Parkinson's

Margot Kim Image
Tuesday, March 31, 2015
BP Med for Parkinson's
Parkinson's disease affects about six-million people worldwide. There is no cure. But researchers are learning more and more about the disease every day. Now, an old drug may offer patients new hope.

FRESNO, Calif. (KFSN) -- Parkinson's disease affects about six-million people worldwide. There is no cure. But researchers are learning more and more about the disease every day. Now, an old drug may offer patients new hope.

Dr. David Higgins lives a busy and active life. But a few years ago, some mysterious symptoms threatened to slow him down.

"I was having trouble swimming, and I was having trouble running," David Higgins told Ivanhoe.

"Stiffness, soreness, lack of control," Higgins explained.

David was diagnosed with Parkinson's, a disease that affects movement.

Higgins said, "It does not make me feel good about the future."

But neurologist Irene Litvan says the future is looking brighter for people like David. She's studying a new therapy for Parkinson's that's already being used to treat high blood pressure.

"So the good thing is multiple people have taken it," said Irene Litvan, M.D., Professor of Neurology at UC San Diego Department of Neural Science and Director of the Movement Disorder Center.

Isradipine works by blocking calcium channels in the body. Researchers believe calcium may be overexpressed in people with Parkinson's. Animal studies show calcium blockers may slow Parkinson's, and people who take the drug for high blood pressure are less likely to develop the disease.

"Hopefully, it will slow the progression of the disease, and ideally, it would stop the progression of the disease," said Dr. Litvan.

A Phase II study found it was safe to use in Parkinson's patients. Now, a larger trial will determine if isradipine can slow the disease. David is hopeful.

"There is hope for more effective therapies and perhaps even a cure," said Higgins.

Until then, he'll stay as active as he can for as long as he can.

Dr. Litvan says patients would probably have to take the medication for the rest of their lives to benefit. Researchers are still enrolling patients in this clinical trial.